## RMD: ResMed Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.4% below STRENGTH zone (4.0-10.0%); PEG 1.86 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (58% of avg), momentum weakening (-3.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($235.32)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. ResMed Inc. $RMD Stock Holdings Trimmed by Skandinaviska Enskilda Banken AB publ**
- Source: MarketBeat | 20251130T121400 | Somewhat-Bullish | Relevance: 99%
- Skandinaviska Enskilda Banken AB publ significantly reduced its stake in ResMed Inc. (NYSE:RMD) by 34.2% in the second quarter, selling over 70,000 shares. Despite this, ResMed reported strong quarterly earnings, beating EPS estimates and achieving a 9.1% year-over-year revenue increase, leading to a "Moderate Buy" consensus rating from analysts. Insider transactions show varied activity, with some selling shares while institutional investors collectively own a substantial portion of the company.

**2. Neuberger Berman Group LLC Purchases 22,431 Shares of ResMed Inc. $RMD**
- Source: MarketBeat | 20251130T122155 | Bullish | Relevance: 98%
- Neuberger Berman Group LLC significantly increased its stake in ResMed Inc. by 71.2% during the second quarter, adding 22,431 shares to its holdings, which are now valued at approximately $13.91 million. The article details ResMed's strong Q2 performance, beating EPS and revenue expectations, and highlights current analyst ratings as "Moderate Buy" with a target price of $297.45. It also covers recent insider sales and ResMed's announced quarterly dividend.

**3. American Century Companies Inc. Has $45.38 Million Stock Holdings in ResMed Inc. $RMD**
- Source: MarketBeat | 20251130T081517 | Bullish | Relevance: 98%
- American Century Companies Inc. increased its stake in ResMed Inc. by 0.7% to 175,901 shares, valued at approximately $45.38 million. This increase comes as ResMed reported strong earnings, beating analyst expectations with an EPS of $2.55 and a 9.1% year-over-year revenue increase. The article also details other institutional investor activity, insider trades, ResMed's stock performance metrics, and recent analyst ratings, highlighting a "Moderate Buy" consensus.

**4. Russell Investments Group Ltd. Buys 8,601 Shares of ResMed Inc. $RMD**
- Source: MarketBeat | 20251201T111414 | Somewhat-Bullish | Relevance: 98%
- Russell Investments Group Ltd. increased its stake in ResMed Inc. by 10.1% in Q2, acquiring 8,601 additional shares to hold a total of 93,789 shares valued at $24.18 million. Despite this institutional buying, ResMed insiders, including CEO Michael J. Farrell, have recently been net sellers of the stock. The company reported strong Q3 earnings, beating analyst estimates, and announced a quarterly dividend of $0.60 per share.

**5. ResMed (RMD) Dropped from Goldman Sachs' APAC Conviction List**
- Source: GuruFocus | 20251201T052500 | Neutral | Relevance: 98%
- ResMed (RMD) has been removed from Goldman Sachs' APAC Conviction List, indicating a shift in the firm's strategic outlook for the company. Despite this, ResMed demonstrates strong financial health with robust revenue growth, profitability, and balance sheet metrics, particularly in the respiratory care device market. The removal could impact investor sentiment, although analyst sentiment remains cautiously optimistic.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 18 ($9.51M) |
| Sells | 14 ($4.85M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 13.1% (+1.6%)
- Blackrock Inc.: 8.4% (-1.3%)
- State Street Corpora: 4.5% (-1.0%)
- Bank Of New York Mel: 3.1% (-9.8%)
- Geode Capital Manage: 2.9% (+0.9%)

### Key Risks

1. Insider selling cluster: $4.9M in recent transactions.
2. Elevated short interest (8.2%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.86 elevated, pricing in significant growth expectations. Forward P/E 20.7x stretched relative to 10% growth. Quality metrics strong (ROE 25%, ROA 14%, margin 27%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.36). Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $36.7B |
| Beta | 0.87 |
| 52W Range | $199.92 - $293.81 |
| Short Interest | 8.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.86 |
| Forward P/E | 20.7 |
| Current P/E | 22.8 |
| YoY Growth | 10.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.8% to -1.4% (-3.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.4pp (needs >4.0% for momentum thesis). Below SMA200 (0.98x), long-term trend not supportive. MACD histogram positive (1.38), confirming momentum. RSI neutral at 42. Volume at 58% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.41% (CS: 33) | Neutral |
| RSI_14 | 42.5 | Neutral |
| MACD Histogram | 1.38 | Bullish |
| vs SMA20 | 0.996x | Below |
| vs SMA50 | 0.950x | Below |
| vs SMA200 | 0.984x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $248.38
- **Stop Loss:** $235.32 (5.3% risk)
- **Target:** $261.44 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 57
- **Position Value:** $14,157.66
- **Portfolio %:** 14.16%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-05 (Est: $2.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.55 | +2.0% |
| 2025Q2 | $2.48 | $2.55 | +2.8% |
| 2025Q1 | $2.36 | $2.37 | +0.4% |
| 2024Q4 | $2.31 | $2.43 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*